Neuronal protein synuclein γ predicts poor clinical outcome in breast cancer

被引:52
作者
Guo, Jianping
Shou, Chengchao [1 ]
Meng, Lin
Jiang, Beihai
Bin Dong
Yao, Lihua
Xie, Yuntao
Zhang, Jianzhi
Chen, Yiding
Budman, Daniel R.
Shi, Yuenian Eric
机构
[1] Peking Univ, Sch Oncol, Beijing Canc hosp & inst, Dept Radiat Oncol, Beijing 100871, Peoples R China
[2] Albert Einstein Coll Med, N Shore Long Island Jewish Hlth Syst, Feinstein Inst Med Res, Bronx, NY 10467 USA
关键词
synuclein gamma; breast cancer; prognosis; chaperone protein; ESTROGEN-RECEPTOR; ALPHA-SYNUCLEIN; ABERRANT EXPRESSION; GENE; METASTASIS; PROMOTES; IDENTIFICATION; STIMULATION; MECHANISMS; COMPONENT;
D O I
10.1002/ijc.22763
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Synuclein 7 (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium. SNCG regulates many pathways in growth and progression of breast cancer. To determine if SNCG is a biomarker for clinical prognosis of breast cancer, we generated a panel of murine monoclonal antibodies (mAbs) against human SNCG and correlated SNCG protein expression in 358 clinical breast cancer specimens with clinical outcome. A panel of 14 mAbs was characterized by ELISA, immunoprecipitation (IP), Western blot, immunocytochemistry and immunohistochemistry. SNCG protein expression was determined in 438 clinical breast specimens by immunohistochemical analysis using mAb 5C5. Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status. While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG. SNCG protein was not detectable in normal tissue adjacent to breast cancer. After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significfintly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG. Multivariate analysis demonstrated that SNCG was a strong independent prognostic variable. SNCG is a new unfavorable prognostic marker for breast cancer progression and a potential target for breast cancer treatment. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:1296 / 1305
页数:10
相关论文
共 32 条
[1]  
Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO
[2]  
2-9
[3]   The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease [J].
Clayton, DF ;
George, JM .
TRENDS IN NEUROSCIENCES, 1998, 21 (06) :249-254
[4]  
Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO
[5]  
2-4
[6]   Expression of α-, β-, and γ-synuclein in glial tumors and medulloblastomas [J].
Fung, KM ;
Rorke, LB ;
Giasson, B ;
Lee, VMY ;
Trojanowski, JQ .
ACTA NEUROPATHOLOGICA, 2003, 106 (02) :167-175
[7]  
George JM, 2002, GENOME BIOL, V3
[8]   Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1 [J].
Gupta, A ;
Inaba, S ;
Wong, OK ;
Fang, GW ;
Liu, JW .
ONCOGENE, 2003, 22 (48) :7593-7599
[9]  
Gupta A, 2003, CANCER RES, V63, P664
[10]   Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells [J].
Inaba, S ;
Li, C ;
Shi, YE ;
Song, DQ ;
Jiang, JD ;
Liu, JW .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (01) :25-35